Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression

  • Israel Lowy,

Press/Media

Period25 Jun 2021

Media coverage

7

Media coverage